We found that peripheral blood CD4 + T cells from patients with active rheumatoid arthritis ( RA) were able to produce greater amounts of interferon gamma after CD3 and CD28 costimulation in the presence of 1 ng / ml IL - 10 than were normal control CD4 + T cells, although their surface expression of the type 1 IL - 10 receptor was increased.	"CD4	31	34	Protein"	"interferon gamma	138	154	Protein"	"CD28	169	173	Protein"	"IL - 10	217	224	Protein"	"CD4	250	253	Protein"	"type 1 IL - 10 receptor	306	329	Protein"	"[{""token"": ""CD4"", ""start_span"": 31, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""interferon gamma"", ""start_span"": 138, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""CD28"", ""start_span"": 169, ""end_span"": 173, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 217, ""end_span"": 224, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 250, ""end_span"": 253, ""type"": ""Protein""}, {""token"": ""type 1 IL - 10 receptor"", ""start_span"": 306, ""end_span"": 329, ""type"": ""Protein""}]"
IL - 10 binds to the IL - 10 receptor ( IL - 10R) complex that is composed of two subunits, the primary ligand - binding component type 1 IL - 10R ( IL - 10R1) and the accessory component type 2 IL - 10R [ 1].	"IL - 10	0	7	Protein"	"IL - 10 receptor	21	37	Protein"	"IL - 10R	40	48	Protein"	"type 1 IL - 10R	131	146	Protein"	"IL - 10R1	149	158	Protein"	"type 2 IL - 10R	188	203	Protein"	"[{""token"": ""IL - 10"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""IL - 10 receptor"", ""start_span"": 21, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""IL - 10R"", ""start_span"": 40, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""type 1 IL - 10R"", ""start_span"": 131, ""end_span"": 146, ""type"": ""Protein""}, {""token"": ""IL - 10R1"", ""start_span"": 149, ""end_span"": 158, ""type"": ""Protein""}, {""token"": ""type 2 IL - 10R"", ""start_span"": 188, ""end_span"": 203, ""type"": ""Protein""}]"
The interaction of IL - 10 and IL - 10R engages the Janus kinase ( JAK) family tyrosine kinases Jak1 and Tyk2, which are constitutively associated with IL - 10R1 and type 2 IL - 10R, respectively [ 2].	"IL - 10	19	26	Protein"	"IL - 10R	31	39	Protein"	"Jak1	96	100	Protein"	"Tyk2	105	109	Protein"	"IL - 10R1	152	161	Protein"	"type 2 IL - 10R	166	181	Protein"	"[{""token"": ""IL - 10"", ""start_span"": 19, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""IL - 10R"", ""start_span"": 31, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""Jak1"", ""start_span"": 96, ""end_span"": 100, ""type"": ""Protein""}, {""token"": ""Tyk2"", ""start_span"": 105, ""end_span"": 109, ""type"": ""Protein""}, {""token"": ""IL - 10R1"", ""start_span"": 152, ""end_span"": 161, ""type"": ""Protein""}, {""token"": ""type 2 IL - 10R"", ""start_span"": 166, ""end_span"": 181, ""type"": ""Protein""}]"
Recent studies indicate that SOCS3 plays a key role in regulating the divergent action of IL - 10 and IL - 6, by specifically blocking STAT3 activation induced by IL - 6 but not that induced by IL - 10 [ 8, 9].	"SOCS3	29	34	Protein"	"IL - 10	90	97	Protein"	"IL - 6	102	108	Protein"	"STAT3	135	140	Protein"	"IL - 6	163	169	Protein"	"IL - 10	194	201	Protein"	"[{""token"": ""SOCS3"", ""start_span"": 29, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 90, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 102, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 135, ""end_span"": 140, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 163, ""end_span"": 169, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 194, ""end_span"": 201, ""type"": ""Protein""}]"
These results indicate that STAT3 is the major IL - 10 - activated STAT in CD4 + T cells, and IL - 10 - induced STAT3 activation may be diminished in active RA, in association with sustained STAT3 phosphorylation.	"STAT3	28	33	Protein"	"IL - 10	47	54	Protein"	"CD4	75	78	Protein"	"IL - 10	94	101	Protein"	"STAT3	112	117	Protein"	"STAT3	191	196	Protein"	"[{""token"": ""STAT3"", ""start_span"": 28, ""end_span"": 33, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 47, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 75, ""end_span"": 78, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 94, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 112, ""end_span"": 117, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 191, ""end_span"": 196, ""type"": ""Protein""}]"
SOCS3 has recently been shown to specifically inhibit STAT3 activation induced by IL - 6 but not by IL - 10, thereby regulating the divergent action of IL - 6 and IL - 10 [ 8, 9].	"SOCS3	0	5	Protein"	"STAT3	54	59	Protein"	"IL - 6	82	88	Protein"	"IL - 10	100	107	Protein"	"IL - 6	152	158	Protein"	"IL - 10	163	170	Protein"	"[{""token"": ""SOCS3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 54, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 82, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 100, ""end_span"": 107, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 152, ""end_span"": 158, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 163, ""end_span"": 170, ""type"": ""Protein""}]"
To determine whether SOCSs were involved in the defective IL - 10 - induced STAT3 activation of RA CD4 + T cells, the levels of SOCS1 and SOCS3 mRNA expression in PB CD4 + T cells from active RA patients and from healthy controls were compared by semiquantitative real - time PCR.	"IL - 10	58	65	Protein"	"STAT3	76	81	Protein"	"CD4	99	102	Protein"	"SOCS1	128	133	Protein"	"SOCS3	138	143	Protein"	"CD4	166	169	Protein"	"[{""token"": ""IL - 10"", ""start_span"": 58, ""end_span"": 65, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 76, ""end_span"": 81, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 99, ""end_span"": 102, ""type"": ""Protein""}, {""token"": ""SOCS1"", ""start_span"": 128, ""end_span"": 133, ""type"": ""Protein""}, {""token"": ""SOCS3"", ""start_span"": 138, ""end_span"": 143, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 166, ""end_span"": 169, ""type"": ""Protein""}]"
These findings indicate that CD4 + T cells become resistant to the inhibitory effect of IL - 10 before migration into the inflamed ST, and suggest that this resistance may be attributable to impaired IL - 10 - dependent STAT3 activation, in association with sustained STAT3 phosphorylation and SOCS1 induction.	"CD4	29	32	Protein"	"IL - 10	88	95	Protein"	"IL - 10	200	207	Protein"	"STAT3	220	225	Protein"	"STAT3	268	273	Protein"	"SOCS1	294	299	Protein"	"[{""token"": ""CD4"", ""start_span"": 29, ""end_span"": 32, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 88, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 200, ""end_span"": 207, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 220, ""end_span"": 225, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 268, ""end_span"": 273, ""type"": ""Protein""}, {""token"": ""SOCS1"", ""start_span"": 294, ""end_span"": 299, ""type"": ""Protein""}]"
The activation of both the extracellular stimulus - regulated kinase and p38 kinase pathways, induced by TNF - alpha and IL - 1, inhibits the Jak1 - STAT3 signaling pathway shared by IL - 10 and IL - 6 in adhered macrophages [ 13].	"TNF - alpha	105	116	Protein"	"IL - 1	121	127	Protein"	"Jak1	142	146	Protein"	"STAT3	149	154	Protein"	"IL - 10	183	190	Protein"	"IL - 6	195	201	Protein"	"[{""token"": ""TNF - alpha"", ""start_span"": 105, ""end_span"": 116, ""type"": ""Protein""}, {""token"": ""IL - 1"", ""start_span"": 121, ""end_span"": 127, ""type"": ""Protein""}, {""token"": ""Jak1"", ""start_span"": 142, ""end_span"": 146, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 149, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 183, ""end_span"": 190, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 195, ""end_span"": 201, ""type"": ""Protein""}]"
STAT3 is activated by a variety of cytokines, notably the IL - 6 family of cytokines ( e. g. IL - 6, IL - 11, leukemia inhibitory factor, and oncostatin M) and growth factors, in addition to IL - 10 [ 4].	"STAT3	0	5	Protein"	"IL - 6	58	64	Protein"	"IL - 11	101	108	Protein"	"leukemia inhibitory factor	110	136	Protein"	"oncostatin M	142	154	Protein"	"IL - 10	191	198	Protein"	"[{""token"": ""STAT3"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 58, ""end_span"": 64, ""type"": ""Protein""}, {""token"": ""IL - 11"", ""start_span"": 101, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""leukemia inhibitory factor"", ""start_span"": 110, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""oncostatin M"", ""start_span"": 142, ""end_span"": 154, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 191, ""end_span"": 198, ""type"": ""Protein""}]"
However, it is also possible that STAT3 activity could be constitutively induced in CD4 + T cells by their own IL - 10 secretion, leading to the loss of sensitivity to exogenous IL - 10, because RA CD4 + T cells in the ST are capable of producing significant levels of IL - 10 [ 34].	"STAT3	34	39	Protein"	"CD4	84	87	Protein"	"IL - 10	111	118	Protein"	"IL - 10	178	185	Protein"	"CD4	198	201	Protein"	"IL - 10	269	276	Protein"	"[{""token"": ""STAT3"", ""start_span"": 34, ""end_span"": 39, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 84, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 111, ""end_span"": 118, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 178, ""end_span"": 185, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 198, ""end_span"": 201, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 269, ""end_span"": 276, ""type"": ""Protein""}]"
In addition, the involvement of other essential proinflammatory cytokines in this process was suggested by our preliminary experiments demonstrating that IL - 10 - mediated IFN - gamma inhibition in CD4 + T cells was reduced by pretreatment with IL - 1beta and TNF - alpha, although less effectively than by IL - 6 ( data not shown).	"IL - 10	154	161	Protein"	"IFN - gamma	173	184	Protein"	"CD4	199	202	Protein"	"IL - 1beta	246	256	Protein"	"TNF - alpha	261	272	Protein"	"IL - 6	308	314	Protein"	"[{""token"": ""IL - 10"", ""start_span"": 154, ""end_span"": 161, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 173, ""end_span"": 184, ""type"": ""Protein""}, {""token"": ""CD4"", ""start_span"": 199, ""end_span"": 202, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 246, ""end_span"": 256, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 261, ""end_span"": 272, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 308, ""end_span"": 314, ""type"": ""Protein""}]"
IL - 12 - induced STAT4 activation is inhibited by SOCS3 induction in Th2 cells, whereas IL - 4 - induced STAT6 signaling is diminished by SOCS1 induction in Th1 cells.	"IL - 12	0	7	Protein"	"STAT4	18	23	Protein"	"SOCS3	51	56	Protein"	"IL - 4	89	95	Protein"	"STAT6	106	111	Protein"	"SOCS1	139	144	Protein"	"[{""token"": ""IL - 12"", ""start_span"": 0, ""end_span"": 7, ""type"": ""Protein""}, {""token"": ""STAT4"", ""start_span"": 18, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""SOCS3"", ""start_span"": 51, ""end_span"": 56, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 89, ""end_span"": 95, ""type"": ""Protein""}, {""token"": ""STAT6"", ""start_span"": 106, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""SOCS1"", ""start_span"": 139, ""end_span"": 144, ""type"": ""Protein""}]"
SOCS1 and SOCS3 may thus have important roles as Th1 - specific and Th2 - specific, mutually exclusive, cross - talk repressors of the IL - 4 - STAT6 and the IL - 12 - STAT4 signaling pathways, respectively.	"SOCS1	0	5	Protein"	"SOCS3	10	15	Protein"	"IL - 4	135	141	Protein"	"STAT6	144	149	Protein"	"IL - 12	158	165	Protein"	"STAT4	168	173	Protein"	"[{""token"": ""SOCS1"", ""start_span"": 0, ""end_span"": 5, ""type"": ""Protein""}, {""token"": ""SOCS3"", ""start_span"": 10, ""end_span"": 15, ""type"": ""Protein""}, {""token"": ""IL - 4"", ""start_span"": 135, ""end_span"": 141, ""type"": ""Protein""}, {""token"": ""STAT6"", ""start_span"": 144, ""end_span"": 149, ""type"": ""Protein""}, {""token"": ""IL - 12"", ""start_span"": 158, ""end_span"": 165, ""type"": ""Protein""}, {""token"": ""STAT4"", ""start_span"": 168, ""end_span"": 173, ""type"": ""Protein""}]"
CD4 + T cells from active RA patients are characterized by their resistance to IL - 10 inhibition of IFN - gamma production, due to constitutive STAT3 phosphorylation and impaired IL - 10 - mediated STAT3 activation.	"CD4	0	3	Protein"	"IL - 10	79	86	Protein"	"IFN - gamma	101	112	Protein"	"STAT3	145	150	Protein"	"IL - 10	180	187	Protein"	"STAT3	199	204	Protein"	"[{""token"": ""CD4"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 79, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""IFN - gamma"", ""start_span"": 101, ""end_span"": 112, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 145, ""end_span"": 150, ""type"": ""Protein""}, {""token"": ""IL - 10"", ""start_span"": 180, ""end_span"": 187, ""type"": ""Protein""}, {""token"": ""STAT3"", ""start_span"": 199, ""end_span"": 204, ""type"": ""Protein""}]"
When treated with MCP - 1 ( 10 ng / ml) or IL - 6 ( 10 ng / ml), significant upregulations of IL - 17 proteins were observed ( 62 + / - 42 and 50 + / - 10 versus 31 + / - 11 pg / ml, respectively; P < 0. 05), whereas none was observed with IL - 8 ( 10 ng / ml), MIP - 1alpha ( 10 ng / ml) or MIP - 1beta ( 10 ng / ml) ( Fig. 2b).	"MCP - 1	18	25	Protein"	"IL - 6	43	49	Protein"	"IL - 17	94	101	Protein"	"IL - 8	240	246	Protein"	"MIP - 1alpha	262	274	Protein"	"MIP - 1beta	292	303	Protein"	"[{""token"": ""MCP - 1"", ""start_span"": 18, ""end_span"": 25, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 43, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""IL - 17"", ""start_span"": 94, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 240, ""end_span"": 246, ""type"": ""Protein""}, {""token"": ""MIP - 1alpha"", ""start_span"": 262, ""end_span"": 274, ""type"": ""Protein""}, {""token"": ""MIP - 1beta"", ""start_span"": 292, ""end_span"": 303, ""type"": ""Protein""}]"
To investigate whether the interaction with CtBP2 is required for Sox6 repression of the epsilony promoter, we introduced a point mutation ( L386H) in the Sox6 protein that has been previously reported to be sufficient to abolish Sox6 - CtBP2 interaction [ 5].	"CtBP2	44	49	Protein"	"Sox6	66	70	Protein"	"epsilony	89	97	Protein"	"Sox6	155	159	Protein"	"Sox6	230	234	Protein"	"CtBP2	237	242	Protein"	"[{""token"": ""CtBP2"", ""start_span"": 44, ""end_span"": 49, ""type"": ""Protein""}, {""token"": ""Sox6"", ""start_span"": 66, ""end_span"": 70, ""type"": ""Protein""}, {""token"": ""epsilony"", ""start_span"": 89, ""end_span"": 97, ""type"": ""Protein""}, {""token"": ""Sox6"", ""start_span"": 155, ""end_span"": 159, ""type"": ""Protein""}, {""token"": ""Sox6"", ""start_span"": 230, ""end_span"": 234, ""type"": ""Protein""}, {""token"": ""CtBP2"", ""start_span"": 237, ""end_span"": 242, ""type"": ""Protein""}]"
However, unlike epsilony globin, zeta and betah1 decline in expression by day 18. 5 dpc ( Figure 1), suggesting that epsilony is regulated differently than zeta and betah1.	"epsilony globin	16	31	Protein"	"zeta	33	37	Protein"	"betah1	42	48	Protein"	"epsilony	117	125	Protein"	"zeta	156	160	Protein"	"betah1	165	171	Protein"	"[{""token"": ""epsilony globin"", ""start_span"": 16, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""zeta"", ""start_span"": 33, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""betah1"", ""start_span"": 42, ""end_span"": 48, ""type"": ""Protein""}, {""token"": ""epsilony"", ""start_span"": 117, ""end_span"": 125, ""type"": ""Protein""}, {""token"": ""zeta"", ""start_span"": 156, ""end_span"": 160, ""type"": ""Protein""}, {""token"": ""betah1"", ""start_span"": 165, ""end_span"": 171, ""type"": ""Protein""}]"
Despite an activation of nuclear factor ( NF) kappaB, NFinterleukin ( IL) - 6 and NFAT similar to LPS or TSST - 1, we observed no significant production of IL - 1beta, IL - 6, tumor necrosis factor alpha or interferon gamma induced by glucan phosphate.	"NFAT	82	86	Protein"	"TSST - 1	105	113	Protein"	"IL - 1beta	156	166	Protein"	"IL - 6	168	174	Protein"	"tumor necrosis factor alpha	176	203	Protein"	"interferon gamma	207	223	Protein"	"[{""token"": ""NFAT"", ""start_span"": 82, ""end_span"": 86, ""type"": ""Protein""}, {""token"": ""TSST - 1"", ""start_span"": 105, ""end_span"": 113, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 156, ""end_span"": 166, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 168, ""end_span"": 174, ""type"": ""Protein""}, {""token"": ""tumor necrosis factor alpha"", ""start_span"": 176, ""end_span"": 203, ""type"": ""Protein""}, {""token"": ""interferon gamma"", ""start_span"": 207, ""end_span"": 223, ""type"": ""Protein""}]"
Results by Schulte and colleagues [ 28] pointed to an induction of IL - 8 transcription depending on activation via an NFkappaB p65 / 65 homodimer, rather than via p65 / 50 heterodimers, which might be the case for the GP - mediated IL - 8 transcription.	"IL - 8	67	73	Protein"	"p65	128	131	Protein"	"65	134	136	Protein"	"p65	164	167	Protein"	"50	170	172	Protein"	"IL - 8	233	239	Protein"	"[{""token"": ""IL - 8"", ""start_span"": 67, ""end_span"": 73, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 128, ""end_span"": 131, ""type"": ""Protein""}, {""token"": ""65"", ""start_span"": 134, ""end_span"": 136, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 164, ""end_span"": 167, ""type"": ""Protein""}, {""token"": ""50"", ""start_span"": 170, ""end_span"": 172, ""type"": ""Protein""}, {""token"": ""IL - 8"", ""start_span"": 233, ""end_span"": 239, ""type"": ""Protein""}]"
Mainly, GP altered the TSST - 1 - induced IL - 1beta / IL - 1RA ratio from a pro - to an anti - inflammatory profile via down - regulation of IL - 1beta and IL - 6, at the same time there was a synergistic up - regulation of IL - 1RA.	"TSST - 1	23	31	Protein"	"IL - 1beta	42	52	Protein"	"IL - 1RA	55	63	Protein"	"IL - 1beta	142	152	Protein"	"IL - 6	157	163	Protein"	"IL - 1RA	225	233	Protein"	"[{""token"": ""TSST - 1"", ""start_span"": 23, ""end_span"": 31, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 42, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 55, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 142, ""end_span"": 152, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 157, ""end_span"": 163, ""type"": ""Protein""}, {""token"": ""IL - 1RA"", ""start_span"": 225, ""end_span"": 233, ""type"": ""Protein""}]"
In this pathway, p100 is processed by the proteasome to p52, which together with the RelB NF - kappaB subunit regulates a distinct set of target genes that control B - cell development, secondary lymphoid organ development, and osteoclastogenesis [ 27] The noncanonical NF - kappaB pathway is strictly dependent on IKK1, which is activated upon phosphorylation by NF - kappaB inducing kinase ( NIK).	"p100	17	21	Protein"	"p52	56	59	Protein"	"RelB	85	89	Protein"	"IKK1	315	319	Protein"	"NF - kappaB inducing kinase	364	391	Protein"	"NIK	394	397	Protein"	"[{""token"": ""p100"", ""start_span"": 17, ""end_span"": 21, ""type"": ""Protein""}, {""token"": ""p52"", ""start_span"": 56, ""end_span"": 59, ""type"": ""Protein""}, {""token"": ""RelB"", ""start_span"": 85, ""end_span"": 89, ""type"": ""Protein""}, {""token"": ""IKK1"", ""start_span"": 315, ""end_span"": 319, ""type"": ""Protein""}, {""token"": ""NF - kappaB inducing kinase"", ""start_span"": 364, ""end_span"": 391, ""type"": ""Protein""}, {""token"": ""NIK"", ""start_span"": 394, ""end_span"": 397, ""type"": ""Protein""}]"
In unstimulated cells, NIK occurs in a cytoplasmic complex with TRAF2, TRAF3, and cIAP1 / 2, which K48 - polyubiquitinates NIK, leading to its continuous degradation by the proteasome.	"NIK	23	26	Protein"	"TRAF2	64	69	Protein"	"TRAF3	71	76	Protein"	"cIAP1	82	87	Protein"	"2	90	91	Protein"	"NIK	123	126	Protein"	"[{""token"": ""NIK"", ""start_span"": 23, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 64, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 71, ""end_span"": 76, ""type"": ""Protein""}, {""token"": ""cIAP1"", ""start_span"": 82, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""2"", ""start_span"": 90, ""end_span"": 91, ""type"": ""Protein""}, {""token"": ""NIK"", ""start_span"": 123, ""end_span"": 126, ""type"": ""Protein""}]"
For example, in B cells TRAF6 is required for CD40 - mediated JNK activation and IL - 6 production, while TRAF2 is required for activation of NF - kappaB, and TRAF3 serves as a negative regulator of CD40 signalling [ 30, 31].	"TRAF6	24	29	Protein"	"CD40	46	50	Protein"	"IL - 6	81	87	Protein"	"TRAF2	106	111	Protein"	"TRAF3	159	164	Protein"	"CD40	199	203	Protein"	"[{""token"": ""TRAF6"", ""start_span"": 24, ""end_span"": 29, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 46, ""end_span"": 50, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 81, ""end_span"": 87, ""type"": ""Protein""}, {""token"": ""TRAF2"", ""start_span"": 106, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""TRAF3"", ""start_span"": 159, ""end_span"": 164, ""type"": ""Protein""}, {""token"": ""CD40"", ""start_span"": 199, ""end_span"": 203, ""type"": ""Protein""}]"
A20 and CYLD are deubiquitinating enzymes that control NF - kappaB activation by targeting specific signalling proteins including RIP1 and TRAF6, to which they are recruited using specific ubiquitin - binding adaptor proteins such as ABIN - 1 and p62.	"A20	0	3	Protein"	"CYLD	8	12	Protein"	"RIP1	130	134	Protein"	"TRAF6	139	144	Protein"	"ABIN - 1	234	242	Protein"	"p62	247	250	Protein"	"[{""token"": ""A20"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""CYLD"", ""start_span"": 8, ""end_span"": 12, ""type"": ""Protein""}, {""token"": ""RIP1"", ""start_span"": 130, ""end_span"": 134, ""type"": ""Protein""}, {""token"": ""TRAF6"", ""start_span"": 139, ""end_span"": 144, ""type"": ""Protein""}, {""token"": ""ABIN - 1"", ""start_span"": 234, ""end_span"": 242, ""type"": ""Protein""}, {""token"": ""p62"", ""start_span"": 247, ""end_span"": 250, ""type"": ""Protein""}]"
Endosomal Toll - like receptors ( TLRs) and cytoplasmic RNA helicase RIG - I - like receptors ( RLRs) or Nod - like receptors ( NLRs) detect the presence of viral single stranded ( TLR7, TLR8, Nod2) or double stranded RNA ( TLR3, RIG - I, MDA5).	"TLR7	181	185	Protein"	"TLR8	187	191	Protein"	"Nod2	193	197	Protein"	"TLR3	224	228	Protein"	"RIG - I	230	237	Protein"	"MDA5	239	243	Protein"	"[{""token"": ""TLR7"", ""start_span"": 181, ""end_span"": 185, ""type"": ""Protein""}, {""token"": ""TLR8"", ""start_span"": 187, ""end_span"": 191, ""type"": ""Protein""}, {""token"": ""Nod2"", ""start_span"": 193, ""end_span"": 197, ""type"": ""Protein""}, {""token"": ""TLR3"", ""start_span"": 224, ""end_span"": 228, ""type"": ""Protein""}, {""token"": ""RIG - I"", ""start_span"": 230, ""end_span"": 237, ""type"": ""Protein""}, {""token"": ""MDA5"", ""start_span"": 239, ""end_span"": 243, ""type"": ""Protein""}]"
We propose that A20 inhibits IAV - induced proinflammatory gene expression ( as shown in our manuscript for TNF, IL - 6, KC, MIP - 2, and IFNbeta) by negatively regulating NF - kappaB and IRF3 activation, which are the major pathways controlling these genes.	"TNF	108	111	Protein"	"IL - 6	113	119	Protein"	"KC	121	123	Protein"	"MIP - 2	125	132	Protein"	"IFNbeta	138	145	Protein"	"IRF3	188	192	Protein"	"[{""token"": ""TNF"", ""start_span"": 108, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 113, ""end_span"": 119, ""type"": ""Protein""}, {""token"": ""KC"", ""start_span"": 121, ""end_span"": 123, ""type"": ""Protein""}, {""token"": ""MIP - 2"", ""start_span"": 125, ""end_span"": 132, ""type"": ""Protein""}, {""token"": ""IFNbeta"", ""start_span"": 138, ""end_span"": 145, ""type"": ""Protein""}, {""token"": ""IRF3"", ""start_span"": 188, ""end_span"": 192, ""type"": ""Protein""}]"
qPCR was performed by using SYBR Green I master mix I ( Roche) in the Lightcycler 480 detection system ( Roche) with the following primers: HPRT: 5 ' - AGTGTTGGATACAGGCCAGAC - 3 ' and 5 ' CGTGATTCAAATCCCTGAAGT - 3 '; IL - 6: 5 ' - GAGGATACCACTCCCAACAGACC - 3 ' and 5 ' - AAGTGCATCATCGTTGTTCATACA - 3 '; IFNbeta: 5 ' - TCAGAATGAGTGGTGGTTGC - 3 ' and 5 ' - GACCTTTCAAATGCAGTAGATTCA - 3 '; A20: 5 ' - AAACCAATGGTGATGGAAACTG - 3 ' and 5 ' - GTTGTCCCATTCGTCATTCC - 3 '; CCL2: 5 ' - TTAAAAACCTGGATCGGAACCAA - 3 ' and 5 ' - GCATTAGCTTCAGATTTACGGGT - 3 '; CXCL1: 5 ' - GAGCCTCTAACCAGTTCCAG - 3 ' and 5 ' - TGAGTGTGGCTATGACTTCG - 3 ' and IFNalpha4: 5 ' - TGATGAGCTACTACTGGTCAGC - 3 ' and 5 ' - GATCTCTTAGCACAAGGATGGC - 3 '.	"IL - 6	217	223	Protein"	"IFNbeta	303	310	Protein"	"A20	387	390	Protein"	"CCL2	465	469	Protein"	"CXCL1	548	553	Protein"	"IFNalpha4	629	638	Protein"	"[{""token"": ""IL - 6"", ""start_span"": 217, ""end_span"": 223, ""type"": ""Protein""}, {""token"": ""IFNbeta"", ""start_span"": 303, ""end_span"": 310, ""type"": ""Protein""}, {""token"": ""A20"", ""start_span"": 387, ""end_span"": 390, ""type"": ""Protein""}, {""token"": ""CCL2"", ""start_span"": 465, ""end_span"": 469, ""type"": ""Protein""}, {""token"": ""CXCL1"", ""start_span"": 548, ""end_span"": 553, ""type"": ""Protein""}, {""token"": ""IFNalpha4"", ""start_span"": 629, ""end_span"": 638, ""type"": ""Protein""}]"
IL - 6, TNF and IFNbeta levels in the supernatant of cells used in ( B) were determined by bioassay ( IL - 6) and ELISA ( TNF and IFNbeta) as described in the ' materials and methods ' section ( D).	"IL - 6	0	6	Protein"	"TNF	8	11	Protein"	"IFNbeta	16	23	Protein"	"IL - 6	102	108	Protein"	"TNF	122	125	Protein"	"IFNbeta	130	137	Protein"	"[{""token"": ""IL - 6"", ""start_span"": 0, ""end_span"": 6, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 8, ""end_span"": 11, ""type"": ""Protein""}, {""token"": ""IFNbeta"", ""start_span"": 16, ""end_span"": 23, ""type"": ""Protein""}, {""token"": ""IL - 6"", ""start_span"": 102, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""TNF"", ""start_span"": 122, ""end_span"": 125, ""type"": ""Protein""}, {""token"": ""IFNbeta"", ""start_span"": 130, ""end_span"": 137, ""type"": ""Protein""}]"
Since p65 - Ser529 and p65 - Ser536 are phosphorylated by TNF - alpha and IL - 1beta [ 41], it is likely that IL - 1beta - mediated p65 - Ser529 / Ser536 phosphorylation may also play a role in SE - induced vasogenic edema.	"p65	6	9	Protein"	"p65	23	26	Protein"	"TNF - alpha	58	69	Protein"	"IL - 1beta	74	84	Protein"	"IL - 1beta	110	120	Protein"	"p65	132	135	Protein"	"[{""token"": ""p65"", ""start_span"": 6, ""end_span"": 9, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 23, ""end_span"": 26, ""type"": ""Protein""}, {""token"": ""TNF - alpha"", ""start_span"": 58, ""end_span"": 69, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 74, ""end_span"": 84, ""type"": ""Protein""}, {""token"": ""IL - 1beta"", ""start_span"": 110, ""end_span"": 120, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Protein""}]"
Quantitative DNaseI footprinting analysis is shown using HIV - 1 LTR fragments ( - 262 to + 4 nt relative to the transcription start site) from HIV - 1Lai / Bal - env - WT and HIV - 1Lai / Bal - env - N5 - Mut and increasing concentrations of recombinant NF - kappaB ( p50 / p65) ( 25 ng, 100 ng, and 500 ng), or NFAT5 ( 10 ng, 50 ng, and 250 ng).	"DNaseI	13	19	Protein"	"env	163	166	Protein"	"env	195	198	Protein"	"p50	269	272	Protein"	"p65	275	278	Protein"	"NFAT5	313	318	Protein"	"[{""token"": ""DNaseI"", ""start_span"": 13, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 163, ""end_span"": 166, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 195, ""end_span"": 198, ""type"": ""Protein""}, {""token"": ""p50"", ""start_span"": 269, ""end_span"": 272, ""type"": ""Protein""}, {""token"": ""p65"", ""start_span"": 275, ""end_span"": 278, ""type"": ""Protein""}, {""token"": ""NFAT5"", ""start_span"": 313, ""end_span"": 318, ""type"": ""Protein""}]"
Quantitative DNaseI footprinting analysis is shown of nucleotides - 262 to + 4 from HIV - 1Lai / Bal - env - WT, HIV - 1Lai / Bal - env - kappaB I - Mut, HIV - 1Lai / Bal - env - kappaB II - Mut, and HIV - 1Lai / Bal - env - kappaB I + II - Mut and increasing concentrations of recombinant NFAT5 ( 10 ng, 50 ng, and 250 ng).	"DNaseI	13	19	Protein"	"env	103	106	Protein"	"env	132	135	Protein"	"env	173	176	Protein"	"env	219	222	Protein"	"NFAT5	290	295	Protein"	"[{""token"": ""DNaseI"", ""start_span"": 13, ""end_span"": 19, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 103, ""end_span"": 106, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 173, ""end_span"": 176, ""type"": ""Protein""}, {""token"": ""env"", ""start_span"": 219, ""end_span"": 222, ""type"": ""Protein""}, {""token"": ""NFAT5"", ""start_span"": 290, ""end_span"": 295, ""type"": ""Protein""}]"
When tested, T308D did not support the downstream phosphorylation of several substrates that were phosphorylated by the Myr - Akt construct in the presence of zVAD including FoxO1, Foxo4, MDM2, and p70S6K ( Fig. S8D).	"T308D	13	18	Protein"	"Myr - Akt	120	129	Protein"	"FoxO1	174	179	Protein"	"Foxo4	181	186	Protein"	"MDM2	188	192	Protein"	"p70S6K	198	204	Protein"	"[{""token"": ""T308D"", ""start_span"": 13, ""end_span"": 18, ""type"": ""Protein""}, {""token"": ""Myr - Akt"", ""start_span"": 120, ""end_span"": 129, ""type"": ""Protein""}, {""token"": ""FoxO1"", ""start_span"": 174, ""end_span"": 179, ""type"": ""Protein""}, {""token"": ""Foxo4"", ""start_span"": 181, ""end_span"": 186, ""type"": ""Protein""}, {""token"": ""MDM2"", ""start_span"": 188, ""end_span"": 192, ""type"": ""Protein""}, {""token"": ""p70S6K"", ""start_span"": 198, ""end_span"": 204, ""type"": ""Protein""}]"
Mouse TNFalpha: forward 5 ' - CCCTCACACTCAGATCATCTTCT - 3 ', reverse 5 ' - GCTACGACGTGGGCTACAG - 3 '; mouse 18S: forward 5 - ' ATAACAGGTCTGTGATGCCCTTAG - 3, reverse 5 ' - CTAAACCATCCAATCGGTAGTAGC - 3 '; human TNFalpha: forward 5 ' - ATGAGCACTGAAAGCATGATCC - 3 ', human TNFalpha: reverse 5 ' - GAGGGCTGATTAGAGAGAGGTC - 3 '; human 18S: forward 5 ' - CAGCCACCCGAGATTGAGCA - 3, human 18S: reverse 5 ' - TAGTAGCGACGGGCGGTGTG - 3 '.	"TNFalpha	6	14	Protein"	"18S	108	111	Protein"	"TNFalpha	209	217	Protein"	"TNFalpha	269	277	Protein"	"18S	329	332	Protein"	"18S	380	383	Protein"	"[{""token"": ""TNFalpha"", ""start_span"": 6, ""end_span"": 14, ""type"": ""Protein""}, {""token"": ""18S"", ""start_span"": 108, ""end_span"": 111, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 209, ""end_span"": 217, ""type"": ""Protein""}, {""token"": ""TNFalpha"", ""start_span"": 269, ""end_span"": 277, ""type"": ""Protein""}, {""token"": ""18S"", ""start_span"": 329, ""end_span"": 332, ""type"": ""Protein""}, {""token"": ""18S"", ""start_span"": 380, ""end_span"": 383, ""type"": ""Protein""}]"
Mouse ribosomal S6 protein ( L - 040893 - 00 and L - 045791 - 00), mouse Akt1 ( L - 040709 - 00), mouse Akt2 ( L - 040782 - 00), mouse Akt3 ( L - 040891 - 00), mouse mTOR ( L - 065427 - 00), mouse PDK1 ( L - 040658 - 00), non - coding control ( D - 001810 - 10 - 05), mouse Mapk8 ( J - 040128 - 05), mouse Mapk9 ( J - 040134 - 05), mouse Jun ( L - 043776 - 00).	"Akt1	73	77	Protein"	"Akt2	104	108	Protein"	"Akt3	135	139	Protein"	"PDK1	197	201	Protein"	"Mapk8	274	279	Protein"	"Mapk9	306	311	Protein"	"[{""token"": ""Akt1"", ""start_span"": 73, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""Akt2"", ""start_span"": 104, ""end_span"": 108, ""type"": ""Protein""}, {""token"": ""Akt3"", ""start_span"": 135, ""end_span"": 139, ""type"": ""Protein""}, {""token"": ""PDK1"", ""start_span"": 197, ""end_span"": 201, ""type"": ""Protein""}, {""token"": ""Mapk8"", ""start_span"": 274, ""end_span"": 279, ""type"": ""Protein""}, {""token"": ""Mapk9"", ""start_span"": 306, ""end_span"": 311, ""type"": ""Protein""}]"
WW domain - containing oxidoreductase, known as WWOX, FOR, or WOX1, is encoded by human or mouse WWOX / Wwox gene.	"WW domain - containing oxidoreductase	0	37	Protein"	"WWOX	48	52	Protein"	"FOR	54	57	Protein"	"WOX1	62	66	Protein"	"WWOX	97	101	Protein"	"Wwox	104	108	Protein"	"[{""token"": ""WW domain - containing oxidoreductase"", ""start_span"": 0, ""end_span"": 37, ""type"": ""Protein""}, {""token"": ""WWOX"", ""start_span"": 48, ""end_span"": 52, ""type"": ""Protein""}, {""token"": ""FOR"", ""start_span"": 54, ""end_span"": 57, ""type"": ""Protein""}, {""token"": ""WOX1"", ""start_span"": 62, ""end_span"": 66, ""type"": ""Protein""}, {""token"": ""WWOX"", ""start_span"": 97, ""end_span"": 101, ""type"": ""Protein""}, {""token"": ""Wwox"", ""start_span"": 104, ""end_span"": 108, ""type"": ""Protein""}]"
p53 induces apoptosis by transactivating proapoptotic genes such as BAX, PUMA, SCOTIN, and FAS, and inhibiting the antiapoptotic gene BCL - 2 ( Lane and Levine, 2010).	"p53	0	3	Protein"	"BAX	68	71	Protein"	"PUMA	73	77	Protein"	"SCOTIN	79	85	Protein"	"FAS	91	94	Protein"	"BCL - 2	134	141	Protein"	"[{""token"": ""p53"", ""start_span"": 0, ""end_span"": 3, ""type"": ""Protein""}, {""token"": ""BAX"", ""start_span"": 68, ""end_span"": 71, ""type"": ""Protein""}, {""token"": ""PUMA"", ""start_span"": 73, ""end_span"": 77, ""type"": ""Protein""}, {""token"": ""SCOTIN"", ""start_span"": 79, ""end_span"": 85, ""type"": ""Protein""}, {""token"": ""FAS"", ""start_span"": 91, ""end_span"": 94, ""type"": ""Protein""}, {""token"": ""BCL - 2"", ""start_span"": 134, ""end_span"": 141, ""type"": ""Protein""}]"
Co - transfection of p53 and p53beta increases p53 - mediated apoptosis, whereas co - expression of p53 with delta133p53 suppresses p53 - mediated apoptosis ( Bourdon et al., 2005).	"p53	21	24	Protein"	"p53beta	29	36	Protein"	"p53	47	50	Protein"	"p53	100	103	Protein"	"delta133p53	109	120	Protein"	"p53	132	135	Protein"	"[{""token"": ""p53"", ""start_span"": 21, ""end_span"": 24, ""type"": ""Protein""}, {""token"": ""p53beta"", ""start_span"": 29, ""end_span"": 36, ""type"": ""Protein""}, {""token"": ""p53"", ""start_span"": 47, ""end_span"": 50, ""type"": ""Protein""}, {""token"": ""p53"", ""start_span"": 100, ""end_span"": 103, ""type"": ""Protein""}, {""token"": ""delta133p53"", ""start_span"": 109, ""end_span"": 120, ""type"": ""Protein""}, {""token"": ""p53"", ""start_span"": 132, ""end_span"": 135, ""type"": ""Protein""}]"
Co - expression of delta133p53beta or delta133p53gamma with p53 does not affect p53 transcriptional activity on p21 and Bax promoters, as well as apoptosis.	"delta133p53beta	19	34	Protein"	"delta133p53gamma	38	54	Protein"	"p53	60	63	Protein"	"p53	80	83	Protein"	"p21	112	115	Protein"	"Bax	120	123	Protein"	"[{""token"": ""delta133p53beta"", ""start_span"": 19, ""end_span"": 34, ""type"": ""Protein""}, {""token"": ""delta133p53gamma"", ""start_span"": 38, ""end_span"": 54, ""type"": ""Protein""}, {""token"": ""p53"", ""start_span"": 60, ""end_span"": 63, ""type"": ""Protein""}, {""token"": ""p53"", ""start_span"": 80, ""end_span"": 83, ""type"": ""Protein""}, {""token"": ""p21"", ""start_span"": 112, ""end_span"": 115, ""type"": ""Protein""}, {""token"": ""Bax"", ""start_span"": 120, ""end_span"": 123, ""type"": ""Protein""}]"
To investigate the importance of C / EBP - beta to endogenous SerpinB2 mRNA expression in response to LPS, we utilized C / EBP - beta - null ( Cebpb - / -) and wild - type MEFs ( Cebpb + / +), since RAW264. 7 cells constitutively express endogenous C / EBP - beta.	"C / EBP - beta	33	47	Protein"	"SerpinB2	62	70	Protein"	"C / EBP - beta	119	133	Protein"	"Cebpb	143	148	Protein"	"Cebpb	179	184	Protein"	"C / EBP - beta	249	263	Protein"	"[{""token"": ""C / EBP - beta"", ""start_span"": 33, ""end_span"": 47, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 62, ""end_span"": 70, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 119, ""end_span"": 133, ""type"": ""Protein""}, {""token"": ""Cebpb"", ""start_span"": 143, ""end_span"": 148, ""type"": ""Protein""}, {""token"": ""Cebpb"", ""start_span"": 179, ""end_span"": 184, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 249, ""end_span"": 263, ""type"": ""Protein""}]"
However, expression of a C / EBP - beta phospho - acceptor site mutant, C / EBPbetaT217A, in Cebpb - / - MEFs did not increase SerpinB2 proximal promoter activity over that of wild - type C / EBP - beta, even though recruitment of C / EBP - betaT217 to the SerpinB2 promoter was observed to decrease following LPS stimulation of RAW264. 7 cells.	"C / EBP - beta phospho - acceptor site mutant	25	70	Protein"	"C / EBPbetaT217A	72	88	Protein"	"Cebpb	93	98	Protein"	"SerpinB2	127	135	Protein"	"C / EBP - beta	188	202	Protein"	"SerpinB2	257	265	Protein"	"[{""token"": ""C / EBP - beta phospho - acceptor site mutant"", ""start_span"": 25, ""end_span"": 70, ""type"": ""Protein""}, {""token"": ""C / EBPbetaT217A"", ""start_span"": 72, ""end_span"": 88, ""type"": ""Protein""}, {""token"": ""Cebpb"", ""start_span"": 93, ""end_span"": 98, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 127, ""end_span"": 135, ""type"": ""Protein""}, {""token"": ""C / EBP - beta"", ""start_span"": 188, ""end_span"": 202, ""type"": ""Protein""}, {""token"": ""SerpinB2"", ""start_span"": 257, ""end_span"": 265, ""type"": ""Protein""}]"
